The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases
Glycosphingolipid (GSL) storage diseases have been the focus of efforts to develop small molecule therapeutics from design, experimental proof of concept studies, and clinical trials. Two primary alternative strategies that have been pursued include pharmacological chaperones and GSL synthase inhibi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2014-07-01
|
| Series: | Journal of Lipid Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520352305 |
| _version_ | 1818934073025888256 |
|---|---|
| author | James A. Shayman Scott D. Larsen |
| author_facet | James A. Shayman Scott D. Larsen |
| author_sort | James A. Shayman |
| collection | DOAJ |
| description | Glycosphingolipid (GSL) storage diseases have been the focus of efforts to develop small molecule therapeutics from design, experimental proof of concept studies, and clinical trials. Two primary alternative strategies that have been pursued include pharmacological chaperones and GSL synthase inhibitors. There are theoretical advantages and disadvantages to each of these approaches. Pharmacological chaperones are specific for an individual glycoside hydrolase and for the specific mutation present, but no candidate chaperone has been demonstrated to be effective for all mutations leading to a given disorder. Synthase inhibitors target single enzymes such as glucosylceramide synthase and inhibit the formation of multiple GSLs. A glycolipid synthase inhibitor could potentially be used to treat multiple diseases, but at the risk of lowering nontargeted cellular GSLs that are important for normal health. The basis for these strategies and specific examples of compounds that have led to clinical trials is the focus of this review. |
| first_indexed | 2024-12-20T04:58:28Z |
| format | Article |
| id | doaj.art-b0348fee051744688c77cf8345ae0f2c |
| institution | Directory Open Access Journal |
| issn | 0022-2275 |
| language | English |
| last_indexed | 2024-12-20T04:58:28Z |
| publishDate | 2014-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Lipid Research |
| spelling | doaj.art-b0348fee051744688c77cf8345ae0f2c2022-12-21T19:52:38ZengElsevierJournal of Lipid Research0022-22752014-07-0155712151225The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseasesJames A. Shayman0Scott D. Larsen1To whom correspondence should be addressed; Department of Internal Medicine and Vahlteich Medicinal Chemistry Core, University of Michigan, Ann Arbor, MI 48109; To whom correspondence should be addressedDepartment of Medicinal Chemistry, University of Michigan, Ann Arbor, MI 48109Glycosphingolipid (GSL) storage diseases have been the focus of efforts to develop small molecule therapeutics from design, experimental proof of concept studies, and clinical trials. Two primary alternative strategies that have been pursued include pharmacological chaperones and GSL synthase inhibitors. There are theoretical advantages and disadvantages to each of these approaches. Pharmacological chaperones are specific for an individual glycoside hydrolase and for the specific mutation present, but no candidate chaperone has been demonstrated to be effective for all mutations leading to a given disorder. Synthase inhibitors target single enzymes such as glucosylceramide synthase and inhibit the formation of multiple GSLs. A glycolipid synthase inhibitor could potentially be used to treat multiple diseases, but at the risk of lowering nontargeted cellular GSLs that are important for normal health. The basis for these strategies and specific examples of compounds that have led to clinical trials is the focus of this review.http://www.sciencedirect.com/science/article/pii/S0022227520352305lysosomeglucosylceramidepharmacological chaperoneeliglustat tartratemiglustatisofagomine |
| spellingShingle | James A. Shayman Scott D. Larsen The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases Journal of Lipid Research lysosome glucosylceramide pharmacological chaperone eliglustat tartrate miglustat isofagomine |
| title | The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases |
| title_full | The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases |
| title_fullStr | The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases |
| title_full_unstemmed | The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases |
| title_short | The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases |
| title_sort | development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases |
| topic | lysosome glucosylceramide pharmacological chaperone eliglustat tartrate miglustat isofagomine |
| url | http://www.sciencedirect.com/science/article/pii/S0022227520352305 |
| work_keys_str_mv | AT jamesashayman thedevelopmentanduseofsmallmoleculeinhibitorsofglycosphingolipidmetabolismforlysosomalstoragediseases AT scottdlarsen thedevelopmentanduseofsmallmoleculeinhibitorsofglycosphingolipidmetabolismforlysosomalstoragediseases AT jamesashayman developmentanduseofsmallmoleculeinhibitorsofglycosphingolipidmetabolismforlysosomalstoragediseases AT scottdlarsen developmentanduseofsmallmoleculeinhibitorsofglycosphingolipidmetabolismforlysosomalstoragediseases |